WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Movie Review: Bill Nighy, Michael Ward shine in Netflix’s Homeless World Cup crowdHere's a look at moon landing hits and missesJudge dismisses lawsuits filed against rapper Drake over deadly Astroworld concertHow do animals react during a total solar eclipse? Scientists plan to find out in AprilLuke Combs leads the 2024 ACM Awards nominations, followed by Morgan Wallen and Megan MoroneyA Dubai company’s staggering land deals in Africa raise fears about risks to Indigenous livelihoodsHow do animals react during a total solar eclipse? Scientists plan to find out in AprilFour astronauts from four countries return to Earth after six months in orbit'Immaculate' review: Things get scary for Sydney Sweeney in a conventWhy don't humans have tails? A genetic mutation offers clues
2.9054s , 6500.1328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Glossary news portal